Cadila Healthcare rallies 9% on strong September quarter results

In Q2FY21, Cadila's Ebitda margins improved by 370 basis points at 22.6% against 18.9% in Q2FY20.

Shares of Cadila Healthcare rallied 9 per cent to Rs 445.60 on the BSE on Tuesday as the company reported strong results in the September quarter (Q2FY21), with net profit after adjusting for exceptional items jumping 73 per cent year-on-year (YoY) at Rs 562 crore, on the back of healthy revenue. The pharmaceutical company's stock was trading close its 52-week high level of Rs 447.95, touched on October 9, 2020.

The company’s consolidated revenues during the quarter grew 13.5 per cent YoY to Rs 3,820 crore against Rs 3,367 crore in Q2FY20. US sales grew a robust 18 per